Search results
Results from the Tech24 Deals Content Network
Viatris (VTRS) delivered earnings and revenue surprises of 8.64% and 0.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris also reaffirmed its full-revenue revenue forecast to the range of $15.5 billion to $16 billion, compared to analysts' estimates of $15.60 billion. Excluding items, the company reported a ...
Viatris is a public company that was formed by the merger of Mylan and Upjohn in 2020. It produces and sells medicines, generics, biosimilars, and active pharmaceutical ingredients worldwide, and has a history of acquisitions and divestitures.
Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
Viatris was formed with the merger of Mylan and Pfizer's Upjohn business and has generic and key branded drugs in its portfolio, including erectile dysfunction drug Viagra, anti-anxiety medication ...
Viatris (VTRS) closed the most recent trading day at $15.17, moving -0.98% from the previous trading session.
Viatris (VTRS) beats on Q3 earnings but misses sales estimates as fluctuations in foreign exchange rates continue to impact results. The company reaffirms guidance.